Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:24 PM
Ignite Modification Date:
2025-12-24 @ 7:24 PM
NCT ID:
NCT00542503
Eligibility Criteria:
Inclusion Criteria:
* Participants must be diagnosed with one of the following conditions:
1. Diabetes with a fasting glucose level greater than or equal to 126 mg/dl and has been receiving treatment for more than 5 years
2. High blood pressure with a history of a systolic blood pressure level greater than 140 mm Hg and a diastolic blood pressure level greater than 85 mm Hg while on medication
3. Coronary artery disease
Exclusion Criteria:
* Prior heart attack encompassing greater than 5% of the left ventricular mass (total MB greater than 3 or Troponin I greater than 2)
* Heart attack, acute coronary syndrome (ACS), or angina within the 1 year prior to study entry
* Medical inability to use any cardiovascular magnetic resonance device (e.g., implanted electronic devices, intracranial metal, claustrophobia, closed angle glaucoma)
* Medically unable to receive dobutamine
* 3-vessel or left main coronary artery disease
* Moderate to severe valvular heart disease
* Left ventricular ejection fraction (LVEF) less than 25%
* History of pulmonary edema
* Serum creatinine level greater than 2.4 mg/dL or estimated glomerular filtration rate (eGFR) less than 30 mL/min
* Use of an investigational drug or device within the 30 days prior to study entry
* Diagnosed with any systemic disease, including cancer, with a reduced life expectancy of less than 12 months
* Chronic atrial fibrillation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
55 Years
Maximum Age:
85 Years
Study:
NCT00542503
Study Brief:
Protocol Section:
NCT00542503